ARCT-2138 (LUNAR-FLU) Phase 1 topline immunogenicity and safety data, anticipated in Q3 ARCT-810 (LUNAR-OTC) Phase 2 and ARCT-032 (LUNAR-CF) Phase 1b interim data and update to be provided on July 1 ...
Arcturus Therapeutics Holdings Inc. ARCT is engaged in developing messenger RNA (mRNA) medicines and vaccines based on its innovative and enabling technologies. San Diego, CA-based Arcturus has ...
Dr Tedros Adhanom Ghebreyesus said 'the virus is still changing and is still capable of causing new waves of diseases and death'. (AFP via Getty Images) The leader of the World Health Organization ...
A new Covid strain behind a surge of infections in India has sparked fears it could also lead to a rise in cases in the UK. Research indicates Arcturus could be one 1.2 times more infectious than the ...
The Arcturus COVID-19 variant has arrived in the United States and is here to stay, according to experts. While it's unclear whether it will drive a summer surge, some doctors are warning that the ...
Hosted on MSN
Arcturus outlines pivotal trial plans and advances CF and OTC programs with regulatory meetings expected in 2026
Earnings Call Insights: Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2025 CEO Joseph E. Payne reported that the ARCT-032 program for Cystic Fibrosis (CF) has completed enrollment and dosing for the 5 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results